Patent classifications
C07C235/52
AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS
The present invention relates to compounds for stabilising the native tetrameric form of transthyretin and protecting it from proteolytic cleavage; compounds for use in the prevention and treatment of transthyretin amyloidosis; and agents and medicaments comprising such compounds. The compounds are based on a general structure A-L-B, wherein A is a group of formula (II) or of formula (III): or of formula (IV) or of formula (V) B is a group of formula (III), (IV), or (V), or a group of formula (VI) or a group of formula —R10Z, wherein: Z is selected from —CO2R′, —CONR′R″, —SO2R′ wherein R′ and R″ are independently H or C1-C4 alkyl; and R10 is a C1-C4 alkylene or alkenylene group; and L represents a linker group which is a saturated or unsaturated chain of 5 to 13 carbon atoms.
##STR00001##
PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITY
This disclosure relates to picolinamides of Formula I and their use as fungicides.
##STR00001##
PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITY
This disclosure relates to picolinamides of Formula I and their use as fungicides.
##STR00001##
Picolinamide compounds with fungicidal activity
This disclosure relates to picolinamides of Formula I and their use as fungicides. ##STR00001##
Picolinamide compounds with fungicidal activity
This disclosure relates to picolinamides of Formula I and their use as fungicides. ##STR00001##
Therapeutic compounds and methods of use thereof
The invention provides compounds having the general Formula (I); ##STR00001##
and pharmaceutically acceptable salts thereof; wherein the variables R.sup.A, R.sup.AA, subscript n, subscript q, ring A, X.sup.2, L, subscript m, X.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
Therapeutic compounds and methods of use thereof
The invention provides compounds having the general Formula (I); ##STR00001##
and pharmaceutically acceptable salts thereof; wherein the variables R.sup.A, R.sup.AA, subscript n, subscript q, ring A, X.sup.2, L, subscript m, X.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS
The present invention relates to an alkoxyphenyl derivative capable of synthesizing an oligonucleotide by a quicker liquid phase synthesis method than in the prior art, a protected nucleoside and a protected nucleotide to which the alkoxyphenyl derivative is bonded, a method for producing an oligonucleotide using the same, and a method for selectively removing the alkoxyphenyl derivative moiety and the like. A compound represented by the general formula (1) or a derivative thereof:
##STR00001##
(In the formula, R each independently represents an optionally substituted alkyl group having 10 to 40 carbons. m represents an integer between 1 and 5. When m is 2 or more, a plurality of ROs may be the same or different. X represents O, S, NH, or NR.sup.N. n represents an integer from 1 to 4. R.sup.N represents an optionally substituted alkyl group having 1 to 6 carbons.)
FATTY ACID ACETYLATED SALICYLATES AND THEIR USES
The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.
FATTY ACID ACETYLATED SALICYLATES AND THEIR USES
The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.